𝐂𝐚𝐬-𝐂𝐋𝐎𝐕𝐄𝐑 𝐢𝐬 𝐦𝐨𝐫𝐞 𝐭𝐡𝐚𝐧 𝐠𝐞𝐧𝐞 𝐞𝐝𝐢𝐭𝐢𝐧𝐠, 𝐢𝐭’𝐬 𝐚 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐚𝐝𝐯𝐚𝐧𝐭𝐚𝐠𝐞.
At BioProcess International Fall Digital Week 2025, Demeetra presented: “𝑼𝒏𝒍𝒐𝒄𝒌𝒊𝒏𝒈 𝒕𝒉𝒆 𝑭𝒖𝒕𝒖𝒓𝒆 𝒐𝒇 𝑩𝒊𝒐𝒍𝒐𝒈𝒊𝒄𝒔 𝑴𝒂𝒏𝒖𝒇𝒂𝒄𝒕𝒖𝒓𝒊𝒏𝒈: 𝑪𝒂𝒔-𝑪𝑳𝑶𝑽𝑬𝑹 𝒇𝒐𝒓 𝑩𝒊𝒈 𝑷𝒉𝒂𝒓𝒎𝒂 & 𝑨𝒅𝒗𝒂𝒏𝒄𝒆𝒅 𝑷𝒊𝒑𝒆𝒍𝒊𝒏𝒆𝒔.”
Jack Crawford, CEO, outlines how Cas-CLOVER tackles two challenges facing Big Pharma today: securing robust commercial FTO and achieving scalable, high-efficiency performance beyond CRISPR and ZFNs. Then Corey Brizzee, PhD Brizzee, Ph.D., shares data-driven results on host cell optimization and multiplexed HCP removal—showing how Cas-CLOVER is transforming cell line development from R&D to GMP scale. With flexible, milestone-free licensing, Cas-CLOVER helps biopharma teams accelerate innovation and ROI.

Access the full webcast recording here to watch on demand.

Demeetra provides integrated genome engineering platforms, and products, backed by deep technical expertise.

Contact us to learn how our differentiated IP, flexible access models, and internal know-how can support adoption from discovery through bioprocessing and commercial use.

Buy Products
Schedule A Call